241 related articles for article (PubMed ID: 22985853)
21. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
[TBL] [Abstract][Full Text] [Related]
22. Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.
Zhou S; Liao H; Liu M; Feng G; Fu B; Li R; Cheng M; Zhao Y; Gong P
Bioorg Med Chem; 2014 Nov; 22(22):6438-52. PubMed ID: 25438768
[TBL] [Abstract][Full Text] [Related]
23. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
[TBL] [Abstract][Full Text] [Related]
25. Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.
Jiang X; Liu H; Song Z; Peng X; Ji Y; Yao Q; Geng M; Ai J; Zhang A
Bioorg Med Chem; 2015 Feb; 23(3):564-78. PubMed ID: 25537530
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors.
Liu J; Yang D; Yang X; Nie M; Wu G; Wang Z; Li W; Liu Y; Gong P
Bioorg Med Chem; 2017 Aug; 25(16):4475-4486. PubMed ID: 28716639
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors.
Wang L; Xu S; Chen X; Liu X; Duan Y; Kong D; Zhao D; Zheng P; Tang Q; Zhu W
Bioorg Med Chem; 2018 Jan; 26(1):245-256. PubMed ID: 29203143
[TBL] [Abstract][Full Text] [Related]
28. Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors.
Weinberg LR; Albom MS; Angeles TS; Husten J; Lisko JG; McHugh RJ; Milkiewicz KL; Murthy S; Ott GR; Theroff JP; Tripathy R; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem Lett; 2011 Jan; 21(1):164-7. PubMed ID: 21123062
[TBL] [Abstract][Full Text] [Related]
29. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Tang Q; Wang L; Tu Y; Zhu W; Luo R; Tu Q; Wang P; Wu C; Gong P; Zheng P
Bioorg Med Chem Lett; 2016 Apr; 26(7):1680-4. PubMed ID: 26923692
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
32. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
33. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.
El Newahie AM; Ismail NS; Abou El Ella DA; Abouzid KA
Arch Pharm (Weinheim); 2016 May; 349(5):309-26. PubMed ID: 27062086
[TBL] [Abstract][Full Text] [Related]
34. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptor.
Galal SA; Abdelsamie AS; Soliman SM; Mortier J; Wolber G; Ali MM; Tokuda H; Suzuki N; Lida A; Ramadan RA; El Diwani HI
Eur J Med Chem; 2013 Nov; 69():115-24. PubMed ID: 24013411
[TBL] [Abstract][Full Text] [Related]
36. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
Qi B; Mi B; Zhai X; Xu Z; Zhang X; Tian Z; Gong P
Bioorg Med Chem; 2013 Sep; 21(17):5246-60. PubMed ID: 23838381
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of new anticancer pyrimidines with multiple-kinase inhibitory effect.
El-Deeb IM; Lee SH
Bioorg Med Chem; 2010 Jun; 18(11):3860-74. PubMed ID: 20471842
[TBL] [Abstract][Full Text] [Related]
39. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Yang Y; Zhang Y; Yang L; Zhao L; Si L; Zhang H; Liu Q; Zhou J
Bioorg Chem; 2017 Feb; 70():126-132. PubMed ID: 28043720
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
